1.1.1 - FDA QMSR Framework, Legal Authority, and Applicability
0% read
FDA QMSR regulatory foundations
FDA QMSR framework, legal authority, and applicability
This lesson develops a defensible method for deciding which quality system requirements apply to an organization's products, activities, and regulatory role. It addresses the framework described in the supplied course blueprint, current as of November 1, 2026.
What you will learn
Explain the relationship between FD&C Act section 520(f), Part 820, and section 501(h). Mapping: Regulatory foundations / legal authority and consequences.
Distinguish incorporated ISO requirements from FDA supplemental requirements. Mapping: Regulatory foundations / QMS obligations.
Assess applicability using product, activity, role, and relevant exceptions. Mapping: Regulatory foundations / organizational applicability.
Differentiate direct manufacturer obligations from supplier controls without assuming that either arrangement eliminates the other. Mapping: Regulatory foundations / supply-chain responsibilities.
Document the evidence, boundary, and unresolved questions supporting an applicability decision. Mapping: Regulatory foundations / implementation and inspection readiness.
Blueprint mapping: FDA QMSR regulatory foundations - legal authority, scope, and applicability, objective bp.d1.t1. Percentage weight is not supplied.
EST. TIME 20-25 minutes. PREREQS None.
OUTPUTS Choose a documented applicability assessment over a title-based assumption; distinguish a direct Part 820 responsibility from a purchasing-control obligation; identify when a conclusion requires additional regulatory evidence.
WHY
Why it matters
The QMSR became effective February 2, 2026. A manufacturer subject to Part 820 must assess its current system against the applicable QMSR framework rather than treat the former QSR as the current governing text.
ISO 13485:2016 alignment does not remove FDA-specific requirements. Scope decisions determine which processes, records, and regulatory interfaces the organization must control.
Incorrectly excluding an activity can leave a compliance gap; automatically assigning every supplier the same obligations can obscure actual responsibilities.
A device may be adulterated under section 501(h) because applicable quality system requirements were not met. A visible product defect is not the only concern.
KEY TERMS
Key Terms & Must-Know Facts
Table 1. Framework reference terms
Term
Working meaning in this lesson
FD&C Act
Federal Food, Drug, and Cosmetic Act, the statutory framework underlying the FDA requirements discussed here.
Section 520(f)
Statutory authority for medical device current good manufacturing practice requirements.
Section 501(h)
Adulteration provision linked to failure to meet applicable device quality system requirements.
21 CFR Part 820
The regulatory home of the FDA Quality Management System Regulation.
QMSR
Quality Management System Regulation, effective February 2, 2026.
QMS
Quality management system: the documented system used to manage applicable quality requirements and interacting processes.
Incorporation by reference
A regulatory mechanism making the identified material part of the applicable regulatory framework.
ISO 13485:2016
The specific medical device QMS standard edition incorporated into the framework described in the blueprint.
ISO 9000:2015 Clause 3
The incorporated source of applicable terminology through section 820.3, rather than incorporation of all ISO 9000 requirements.
Regulatory role
The organization's function in relation to a product and its activities, evaluated against applicable requirements rather than inferred solely from its business title.
Outsourced process
A process performed outside the organization that must be addressed through applicable QMS controls.
Applicability assessment
A documented evaluation linking products, activities, roles, and exceptions to applicable requirements.
Must-know facts
Read sections 820.1 and 820.3 for scope and definitions together with the QMS obligations in section 820.10.
Section 820.7 identifies incorporated material; incorporation does not automatically follow a future ISO edition.
Applicable ISO 13485 requirements and applicable FDA supplemental provisions must both be considered.
Design, manufacture, packaging, labeling, storage, installation, and servicing are activities that warrant scope assessment.
A supplier's participation in the device supply chain does not, by itself, establish identical direct Part 820 obligations.
An outsourced provider may require supplier controls and a separate assessment of its own direct obligations.
Scope boundary: The source pack identifies the applicability framework but does not reproduce complete definitions or exception provisions. Use this lesson to structure a decision. Confirm any specific exclusion or exemption against the applicable authoritative text before relying on it.
CORE
Core content
1.1.1.1 1. Separate legal authority, requirements, and consequences
A Explanation
Decision conflict: Does acceptable product performance settle a quality system concern, or must the applicable process requirements also be evaluated? Choose the requirement-based assessment. A successful product check does not establish that every applicable QMS obligation was met.
WHY THIS IS TESTED: Quality professionals must distinguish the legal basis for a requirement from evidence of conformity and from the possible legal consequence of noncompliance.
Section 520(f) supplies statutory authority for device current good manufacturing practice requirements. Part 820 implements the quality system framework. Section 501(h) addresses adulteration associated with failure to comply with applicable requirements. These references perform different jobs: authority, operative requirements, and consequence. See Fig 1.
Fig 1. Authority, requirements, and consequence Exam takeaway: Identify the applicable quality system obligation before evaluating the consequence of its failure.
flowchart TD; A[FD&C Act section 520f] --> B[Authority for device CGMP requirements]; B --> C[Applicable Part 820 obligations]; C --> D{Applicable requirement unmet?}; D -->|Yes| E[Assess section 501h implications]; D -->|No evidence yet| F[Establish facts and applicability];
Do not convert this relationship into a claim that every documentation discrepancy automatically proves adulteration. First establish the applicable requirement and the facts. Likewise, absence of a complaint does not resolve whether a required control was performed.
Requirement-first reasoning Exam takeaway: Product results and process compliance are separate questions that must be connected by evidence.
Identify the requirement
Confirm applicability
Establish compliance facts
Evaluate consequence and response
B Worked example
Scenario: A 12-year-old manufacturer has expanding production and a delayed training-record migration. A final functional test passes. Its manager also cites a customer satisfaction award and concludes that the record concern has no regulatory significance.
Identify the task: Determine how to assess the QMS issue, not whether the award demonstrates commercial success.
Extract key facts: There is a potential record-control problem; product testing passed; the governing obligation has not yet been identified.
Apply the rule: Connect the activity and record to an applicable requirement before determining conformity.
Eliminate: Neither a passing test nor a satisfaction award establishes compliance with a separate record requirement.
Verify: Review the actual record, required control, scope decision, and evidence of execution; document the resulting finding and route it through the appropriate QMS process.
C Common trap
Wrong conclusion: No product defect means no QMSR concern. Why tempting: Product testing is concrete and readily available. Single eliminating clue: The question concerns a potentially unmet quality system requirement, not merely device performance.
D Checkpoint
A reviewer needs the statutory provision authorizing medical device CGMP requirements. Which reference best fits?
A. FD&C Act section 520(f).
B. FD&C Act section 501(h).
C. 21 CFR section 820.7.
D. ISO 13485:2016.
Answer: A. A is correct because it supplies the authority being asked about. B is tempting because it is another statutory provision, but it addresses the adulteration consequence. C is tempting because it connects standards to the regulation, but it addresses incorporation by reference. D is tempting because it supplies QMS requirements, but it is not the statutory authority.
If you missed this: Review Separate legal authority, requirements, and consequences - focus on the distinct function of section 520(f).
1.1.1.2 2. Read the incorporated standard and FDA provisions together
A Explanation
Decision conflict: Is an ISO-focused requirement list sufficient, or must the organization also identify FDA provisions? Choose a combined applicability map. The blueprint describes section 820.10 as requiring a documented QMS meeting applicable ISO 13485 requirements and other applicable Part 820 provisions.
WHY THIS IS TESTED: A system can appear well organized while its requirements register omits the FDA-specific interfaces that make it usable in the regulated environment.
The final rule was published February 2, 2024, and the QMSR became effective February 2, 2026. The incorporated standard edition identified in the source pack is ISO 13485:2016. ISO 9000:2015 Clause 3 supplies applicable terminology through section 820.3; that does not independently incorporate the whole ISO 9000 standard. See Fig 2.
Fig 2. Combined requirements map Exam takeaway: An applicable QMSR framework includes the incorporated requirements and FDA-specific provisions.
flowchart TD; A[Applicable QMSR framework] --> B[ISO 13485:2016 requirements]; A --> C[Other applicable Part 820 provisions]; A --> D[Terminology through section 820.3]; C --> E[Reporting records labeling and packaging interfaces]; D --> F[ISO 9000:2015 Clause 3];
Table 2. Similar references with different functions
Reference
Use it for
Do not infer
Sections 820.1 and 820.3
Scope and applicable definitions
Every supply-chain organization has identical obligations
Section 820.7
Identifying incorporated material
Every future ISO revision automatically replaces the incorporated edition
Section 820.10
Applicable QMS obligations and linked regulatory interfaces
An ISO-only checklist is necessarily complete
Sections 820.35 and 820.45
FDA-specific records, labeling, and packaging provisions identified in the blueprint
Their applicability can be decided without considering the actual activity
Reporting, UDI, tracking, and traceability are examples of interfaces requiring separate applicability assessment. Their detailed operational rules belong in later course topics; do not import a reporting deadline or tracking obligation into an organization solely because it appears in the same regulatory framework.
Build a usable requirements register Exam takeaway: Map requirements to actual processes and evidence rather than collecting unassigned references.
Confirm incorporated edition
Identify applicable ISO requirements
Add applicable FDA provisions
Assign process and evidence
B Worked example
Scenario: A 7-year-old company has outsourced packaging and a newly implemented electronic document system. Its requirements register cites ISO 13485:2016. A dashboard shows 98% training completion, and a consultant says a future standard edition should replace the current references immediately.
Identify the task: Determine whether the requirements register supports the applicable FDA framework.
Extract key facts: The register lists the incorporated standard but has not mapped FDA supplemental provisions; packaging is outsourced.
Apply the rule: Evaluate applicable ISO requirements together with applicable Part 820 requirements, using the incorporated edition identified in the regulation.
Eliminate: Training completion does not establish register completeness; a future publication does not automatically amend incorporation by reference.
Verify: Check packaging responsibilities, applicable FDA provisions, process ownership, and supporting records in the controlled register.
C Common trap
Wrong conclusion: The newest standard edition is automatically the FDA requirement. Why tempting: Updating to the newest document sounds like good document control. Single eliminating clue: The regulation incorporates an identified edition.
D Checkpoint
Which requirement-mapping approach best matches the supplied framework?
A. Use all ISO 9000 requirements as the complete Part 820 checklist.
B. Use applicable ISO 13485:2016 requirements together with applicable FDA provisions.
C. Use applicable FDA supplemental provisions without the incorporated standard.
D. Replace ISO 13485:2016 whenever a later edition becomes available.
Answer: B. A is tempting because ISO 9000 terminology is incorporated, but the entire standard is not independently incorporated on that basis. B is correct because the framework combines applicable incorporated requirements and FDA provisions. C is tempting because FDA provisions are legally important, but omits the incorporated QMS requirements. D is tempting because current documents matter, but publication alone does not change the incorporated edition.
If you missed this: Review Read the incorporated standard and FDA provisions together - focus on the combined requirements map.
Quick Recall:
Which provision supplies CGMP authority? Section 520(f).
Does a later ISO edition automatically replace the incorporated edition? No.
Complete the pairing: applicable ISO requirements plus applicable ______ provisions. FDA.
1.1.1.3 3. Distinguish direct obligations from supplier controls
A Explanation
Decision conflict: Should the organization classify a business by its name or by the product and activities it actually performs? Choose the activity-based assessment. The label 'supplier' is insufficient evidence either for full direct applicability or for exclusion.
WHY THIS IS TESTED: Outsourcing, specification ownership, and contract services can separate physical work from organizational responsibility. A title-based decision misses those relationships.
Finished device manufacturers, specification developers, contract manufacturers, component suppliers, sterilization providers, initial importers, and outsourced service providers require distinct assessments. A business may have more than one role. In particular, a service performed for a manufacturer may require purchasing or outsourced-process controls while also raising questions about the provider's own direct obligations. See Fig 3.
Fig 3. Two questions for every provider Exam takeaway: Supplier controls and a provider's direct regulatory obligations require separate assessments.
flowchart TD; A[Provider activity and product facts] --> B{Own direct obligations?}; A --> C{Manufacturer supplier controls?}; B --> D[Assess role scope and exceptions]; C --> E[Assess purchased or outsourced process]; D --> F[Document responsibilities]; E --> F;
Table 3. Role differential for applicability assessment
Organization or role
Discriminating question
Practical assessment direction
Finished device manufacturer
What device and manufacturing activities are within its scope?
Assess applicable Part 820 requirements and exceptions for those activities.
Specification developer
Does it define or control device specifications while physical production occurs elsewhere?
Do not exclude it merely because it lacks a production floor; assess its actual regulatory role.
Contract manufacturer
What device-related production activities does it perform?
Evaluate its own applicability separately from the customer's supplier controls.
Component supplier
Is it supplying components, or also performing activities that alter its regulatory role?
Do not assign identical direct obligations solely because its part enters a device.
Sterilization provider
What processing is performed on which products?
Evaluate the processing role; do not presume a service-only description settles applicability.
Initial importer
What import role and additional device activities actually occur?
Separate assessment of other FDA obligations from the Part 820 question.
Outsourced service provider
What process is outsourced, and does its performance create a separate regulated role?
Assess supplier controls and direct applicability independently.
The point is not to assign a universal answer to each row. The available source does not supply every role-specific definition or exception. The defensible output is an evidence-supported conclusion for the actual organization, product, and activity.
Role-based comparison process Exam takeaway: A business label starts the inquiry but cannot finish it.
Describe the product
List actual activities
Assess the regulatory role
Evaluate both responsibility pathways
B Worked example
Scenario: A 9-year-old business has no assembly line and outsources all physical production. It controls finished-device specifications and approves specification changes. Its website calls it a distributor; its office audit reports excellent housekeeping.
Identify the task: Determine the next step in assessing the company's Part 820 scope.
Extract key facts: It controls device specifications and related changes despite outsourcing production.
Apply the rule: Evaluate the specification-development role and associated activities against scope and definitions.
Eliminate: The distributor label, absence of an assembly line, and housekeeping result do not resolve that role.
Verify: Review specification ownership, contracts, change authority, and the applicable definitions before approving the scope statement.
C Common trap
Wrong conclusion: A quality agreement alone establishes the provider's regulatory status. Why tempting: Signed agreements visibly allocate work. Single eliminating clue: Direct applicability depends on the actual role and applicable requirements, not the contract title.
D Checkpoint
A supplier provides a generic component and the available facts establish no additional device activity. What is the most appropriate conclusion?
A. It has the same direct Part 820 obligations as the finished device manufacturer.
B. It is outside all FDA requirements because it supplies a component.
C. Assess the manufacturer's supplier controls and separately confirm whether any direct requirements apply to the supplier.
D. Its purchase order alone determines whether Part 820 applies.
Answer: C. A is tempting because the component affects the device, but supply-chain participation alone is insufficient. B is tempting because components differ from finished devices, but the facts do not support a blanket exemption from all FDA requirements. C is correct because it preserves both assessments without assuming identical obligations. D is tempting because purchasing documents establish expectations, but they do not independently determine regulatory scope.
If you missed this: Review Distinguish direct obligations from supplier controls - focus on the two independent responsibility questions.
1.1.1.4 4. Produce a defensible applicability decision
A Explanation
Decision conflict: Is a single organization-wide label enough, or should the conclusion identify its product and activity boundary? Choose a bounded assessment. An organization may perform different activities for different products at different sites; an unsupported blanket statement conceals these distinctions.
WHY THIS IS TESTED: Quality staff must translate regulatory interpretation into process ownership, controlled records, and reassessment when activities change.
Use product type, manufacturing activities, regulatory role, and applicable exceptions as the core assessment. Record the evidence supporting each conclusion. Where an exception is proposed, identify the exact basis and its limits. If the basis is unavailable, keep the question open and assign follow-up rather than recording a definitive exemption. See Fig 4.
Fig 4. Evidence-based applicability decision tree Exam takeaway: An exception is a conclusion requiring a supported basis, not a substitute for scope analysis.
flowchart TD; A[Define product and activities] --> B[Determine regulatory role]; B --> C{Direct Part 820 applicability supported?}; C -->|Yes| D[Map requirements and supported exceptions]; C -->|Unresolved| E[Obtain missing evidence]; C -->|No within assessed boundary| F[Document basis and supplier interfaces]; D --> G[Assign controls and reassessment]; E --> B; F --> G;
A useful scope record states the entity, site, product family, activity, supporting evidence, applicable requirement, any supported exception, responsible owner, and reassessment trigger. This is a practical implementation structure, not a claim that the source mandates a particular form template.
Close the scope decision Exam takeaway: A documented conclusion should lead to owned controls and a defined response to change.
Collect product and activity evidence
Resolve role and exception questions
Record the bounded conclusion
Assign controls and change triggers
B Worked example
Scenario: A 15-year-old supplier previously sold only components. It now proposes packaging and labeling finished devices and holding them before shipment. Production is expanding, a labeling procedure is still being drafted, and its delivery metric remains 99%. Management wants to reuse the old component-only scope statement.
Identify the task: Decide whether the existing scope conclusion covers the proposed activities.
Extract key facts: Packaging, labeling, and storage introduce activities absent from the earlier assessment.
Apply the rule: Reassess the actual product, activities, role, and relevant exceptions before relying on the old conclusion.
Eliminate: Delivery performance does not address the new regulatory boundary; the historic supplier classification is not decisive.
Verify: Update the scope record, identify applicable controls and owners, and resolve outstanding applicability questions before treating the plan as compliant.
C Common trap
Wrong conclusion: A previous scope assessment remains sufficient until the legal entity changes. Why tempting: The same company name suggests continuity. Single eliminating clue: Its manufacturing activities have changed.
D Checkpoint
An applicability memo asserts an exception but contains no cited basis or description of its limits. What is the best next step?
A. Accept the exception if the organization has used it for several years.
B. Replace the memo with a supplier quality agreement.
C. Obtain the applicable exception basis and evaluate whether the facts satisfy it.
D. Treat the uncertainty as proof that every Part 820 requirement applies without qualification.
Answer: C. A is tempting because historical practice suggests stability, but longevity does not establish a valid exception. B is tempting because an agreement allocates responsibility, but it cannot supply a missing regulatory basis. C is correct because it resolves the decisive evidence gap. D is tempting because it sounds conservative, but uncertainty does not justify an unsupported universal applicability statement.
If you missed this: Review Produce a defensible applicability decision - focus on substantiating an exception before relying on it.
Quick Recall:
True or false: Outsourcing physical production automatically excludes a specification developer. False.
What triggers reassessment in the supplier case? Newly proposed packaging, labeling, and storage activities.
What closes an unsupported exception claim? A verified basis and a demonstrated factual fit.
Visual application gallery
Compare two kinds of scope error in Fig 5, then use Fig 6 to connect your conclusion to implementation.
Fig 5. Over-inclusion versus under-inclusion Exam takeaway: Correct scope avoids both identical-obligation assumptions and unsupported exclusions.
flowchart TD; A[Scope decision] --> B[Over-inclusion]; A --> C[Under-inclusion]; B --> D[All suppliers treated identically]; C --> E[Relevant activities excluded by title]; D --> F[Reassess product activity role and exception]; E --> F;
Fig 6. From scope record to working controls Exam takeaway: An applicability conclusion is useful when it identifies process owners, evidence, and reassessment triggers.
flowchart TD; A[Supported applicability conclusion] --> B[Requirement register]; B --> C[Process owner and controls]; C --> D[Records of execution]; D --> E[Audit and change feedback]; E --> A;
Legal foundation at a glance Exam takeaway: Authority, operating requirements, and consequences have different roles in the compliance assessment.
{"prompt":"Square educational vector illustration on white with blue and gray palette and teal accent. Show three separate panels labeled Authority, Requirements, Consequence. Use a government building, a quality system binder, and an assessment clipboard. Connect panels with simple arrows. Do not show automatic enforcement or a defective device. All labels within generous margins; no figure numbers, gradients, or logos.","caption":"Legal foundation at a glance","size":"1024x1024"}
Two sources of applicable requirements Exam takeaway: Map incorporated requirements and FDA provisions into the same controlled quality system.
{"prompt":"Square clean educational vector diagram, white background, blue gray and teal. Two document stacks labeled ISO 13485:2016 and FDA provisions converge into one binder labeled Applicable QMS. Add a small separate terminology card labeled ISO 9000 Clause 3. No certification seal, no suggestion of future edition replacement, no figure numbers, all text inside wide margins.","caption":"Two sources of applicable requirements","size":"1024x1024"}
Specifications and physical production Exam takeaway: Physical production location alone does not resolve the regulatory role of the specification-controlling organization.
{"prompt":"Square educational vector comparison on white. Left panel labeled Specifications shows a quality professional controlling a generic medical device drawing and change record. Right panel labeled Production shows a contract factory assembling the generic device. Link panels with a document exchange arrow. No automatic legal conclusions. Cool blue gray, teal accent, crisp outlines, no gradients, all labels inside generous margins.","caption":"Specifications and physical production","size":"1024x1024"}
Component supply and finished device activity Exam takeaway: Determine what the provider actually supplies or performs before assigning regulatory responsibilities.
{"prompt":"Square clean vector comparison with two panels. Left labeled Component supply shows a generic unbranded plastic part in a tray. Right labeled Finished device activity shows a quality worker packaging a generic medical device. Between panels show a clipboard labeled Assess role. Do not label either panel exempt or universally regulated. White background, cool blue gray and teal, thin outlines, no gradients, full margins.","caption":"Component supply and finished device activity","size":"1024x1024"}
Separate provider questions Exam takeaway: Assess direct applicability separately from the manufacturer's control of an outsourced process.
{"prompt":"Square educational vector illustration on white showing a generic contract sterilization chamber at center and two clearly distinct clipboards beside it. First clipboard labeled Direct applicability. Second clipboard labeled Supplier controls. Show a quality professional considering both, without checkmarks that imply a predetermined legal conclusion. Blue gray palette, teal accent, no particles, gradients, logos, or figure numbers; generous margins.","caption":"Separate provider questions","size":"1024x1024"}
Applicability evidence workstation Exam takeaway: A defensible scope decision links product, activity, role, and exception evidence.
{"prompt":"Square educational vector scene of a medical device quality professional reviewing four neatly separated cards labeled Product, Activity, Role, Exception. Include generic device drawing, process map, responsibility chart, and reference document respectively. Add an unsigned scope assessment sheet to show evaluation in progress. White background, blue gray teal, no gradients, no legal verdict, no figure numbering, all elements within wide margins.","caption":"Applicability evidence workstation","size":"1024x1024"}
TRAPS
Exam Traps & Differentiators
Common traps & distractors:
Confusing business success with regulatory evidence: Customer satisfaction is tempting because it reflects real performance; the eliminating clue is that the question asks about a specified QMS obligation.
Using one site's conclusion for all operations: A common corporate name is tempting evidence of a shared scope; the eliminating clue is a different product or activity boundary.
Reading an exception more broadly than its basis: A short exemption label is tempting because it simplifies implementation; the eliminating clue is a limitation in the supporting provision that must be matched to the facts.
Looks similar but is not
Use Table 2 to distinguish a reference's function and Table 3 to distinguish an organization's role. A standard reference answers a requirements question; a provider label raises an applicability question. Neither substitutes for evidence about what the organization does.
When the scenario says this, consider this
No factory: Examine who controls specifications and changes.
Service provider: Identify the actual processing or device-related activity.
All suppliers: Challenge a blanket direct-obligation conclusion.
New labeling operation: Revisit the existing scope boundary.
Exception claimed: Obtain the basis and check its limitations.
What comes next: As of the blueprint's November 1, 2026 cutoff, the incorporated edition identified here is ISO 13485:2016. No specific proposed amendment or future incorporation is supplied. Monitor authoritative changes and assess their effective dates rather than treating a possible future revision as an existing requirement. The next topic, QSR-to-QMSR Regulatory Transition, develops migration implications.
ALGO
Algorithm / Approach
Use this five-step approach for a new site, new activity, supplier onboarding, or an organizational change. Record unresolved questions instead of forcing a yes-or-no conclusion without evidence.
1. Bound the assessment: Identify entity, site, product, and proposed or existing activity.
2. Establish the role: Compare actual responsibilities with applicable scope and definitions.
3. Test applicability: Evaluate Part 820 obligations and substantiate any claimed exception.
4. Map responsibilities: Separate direct duties from purchasing and outsourced-process controls; identify overlaps.
5. Close and maintain: Assign owners, record evidence and open items, and define when changes trigger reassessment.
Three-minute workplace check
Which product and activity does your current scope statement actually cover?
Which provider requires two separate responsibility assessments?
Which planned change would make the current conclusion incomplete?
QUIZ
Self-check quiz
Select the most appropriate answer for each situation. Apply only the facts supplied.
1. Legal consequence
An applicable quality system requirement was not met. Which provision is most directly associated with the potential adulteration consequence?
A. FD&C Act section 520(f).
B. FD&C Act section 501(h).
C. 21 CFR section 820.7.
D. ISO 9000:2015 Clause 3.
2. Supply-chain inference
A purchasing manager says every component supplier automatically has the same direct Part 820 duties as the finished device manufacturer. Which response is best?
A. Accept the statement because every component can affect device quality.
B. Replace the supplier's regulatory assessment with the manufacturer's purchase order.
C. Evaluate supplier controls and direct applicability separately using actual product and activity facts.
D. Exclude the supplier from all FDA obligations because it supplies components.
3. Incorporated edition
A future ISO 13485 edition becomes available. No regulatory change is identified in the available facts. What should a QMS requirements register identify as the incorporated edition described in this lesson?
A. The newest published edition.
B. Whichever edition the organization's supplier prefers.
C. ISO 13485:2016.
D. ISO 9000:2015 in place of ISO 13485.
4. Outsourced production
A business controls device specifications but outsources assembly. Its scope memo excludes Part 820 solely because it operates no factory. What is the best next step?
A. Retain the conclusion because physical assembly determines the entire scope.
B. Evaluate the specification-development role and actual responsibilities under the applicable definitions.
C. Accept the exclusion if the assembler has a quality agreement.
D. Apply identical requirements to every organization named in the supply chain.
5. Change and exception
A component supplier plans to package and label finished devices. Its old memo claims an unspecified exception. What is the most appropriate response?
A. Extend the memo because the legal entity is unchanged.
B. Accept the exception after updating the supplier's commercial name.
C. Use the customer's approval as the complete evidence for the exception.
D. Reassess the new activities and verify the exception's basis and limits.
ANSWERS
Answer key & explanations
1. Answer: B
A: Tempting because it is a relevant statutory provision; incorrect because section 520(f) supplies CGMP authority rather than the adulteration provision requested.
B: Correct because section 501(h) is the provision linked to the potential adulteration consequence of noncompliance with applicable requirements.
C: Tempting because incorporation determines the requirements framework; incorrect because section 820.7 is not the adulteration provision.
D: Tempting because terminology affects interpretation; incorrect because the incorporated definitions do not supply the statutory consequence.
If you missed this: Review Separate legal authority, requirements, and consequences - focus on authority versus adulteration.
2. Answer: C
A: Tempting because component quality matters; incorrect because quality impact alone does not establish identical direct regulatory obligations.
B: Tempting because purchase orders communicate requirements; incorrect because commercial documentation does not replace applicability analysis.
C: Correct because it addresses both responsibility pathways using evidence about actual products, activities, and roles.
D: Tempting because a component supplier differs from a finished device manufacturer; incorrect because the available facts do not establish exemption from all FDA obligations.
If you missed this: Review Distinguish direct obligations from supplier controls - focus on why supply-chain participation is insufficient by itself.
3. Answer: C
A: Tempting because document systems should track revisions; incorrect because a new publication does not automatically change regulatory incorporation.
B: Tempting because supplier coordination is useful; incorrect because supplier preference does not select the incorporated regulatory edition.
C: Correct because ISO 13485:2016 is the incorporated edition identified by the supplied framework.
D: Tempting because ISO 9000 terminology is incorporated; incorrect because that terminology does not replace the medical device QMS standard.
If you missed this: Review Read the incorporated standard and FDA provisions together - focus on edition-specific incorporation.
4. Answer: B
A: Tempting because assembly is an obvious manufacturing activity; incorrect because absence of assembly does not settle the specification-controlling organization's role.
B: Correct because it investigates the decisive responsibility before accepting a scope exclusion.
C: Tempting because an agreement documents outsourcing; incorrect because it cannot establish that the specification developer has no direct obligations.
D: Tempting because shared requirements seem administratively simple; incorrect because each role and activity requires its own applicability assessment.
If you missed this: Review Distinguish direct obligations from supplier controls - focus on specification control when production is outsourced.
5. Answer: D
A: Tempting because the organization has not changed identity; incorrect because its activities and assessed boundary have changed.
B: Tempting because administrative updates can make a document appear current; incorrect because they do not substantiate the exception.
C: Tempting because customer approval is relevant to supplier management; incorrect because it is not a substitute for the applicable exception basis.
D: Correct because it addresses both the changed activity and the unsupported regulatory conclusion.
If you missed this: Review Produce a defensible applicability decision - focus on reassessment and supported exception boundaries.
RAPID
Rapid review / cheat-sheet
Authority question → identify the statutory source before discussing implementation.
Conformity question → connect an obligation to evidence of execution.
Scope statement → name the product and activity boundary.
Business title → treat it as a lead to investigate.
Quality agreement → inspect responsibility allocation without assuming it settles direct applicability.
Unresolved exception → identify the missing basis and responsible follow-up owner.
Activity change → ask whether the prior conclusion still covers the work.
Requirements register → connect references to processes, owners, and records.
Key points
Legal authority, QMS obligations, and adulteration consequences are distinct parts of the framework.
Applicable incorporated ISO requirements and FDA provisions must be read together.
Product, activity, role, and supported exceptions determine the scope assessment.
Supplier controls and direct regulatory applicability can coexist and require separate consideration.
See also: QSR-to-QMSR Regulatory Transition; Regulatory Definitions and QMS Scope; Regulatory Compliance and Certification. These neighboring topics develop transition details, definitions, and the distinction between certification and regulatory compliance.
End of your free lesson
Keep going with the full Medical Device QMS: FDA QMSR and ISO 13485 Certificate Program
You just studied the way members do, in the same lesson interface. Full access unlocks every lesson, the question bank and flashcards for a full year.